Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00176644 | Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer | terminated | Phase 2 | 23 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT00483561 | Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 26 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02809690 | 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer | terminated | Phase 1 | 18 | University of Southern CaliforniaOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05437679 | Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System(CHARTER) | terminated | — | 9 | Angle plcINDUSTRY | 1 | Sep 5, 2023 | clinicaltrials |
| NCT00499174 | Observation or Radical Treatment in Patients With Prostate Cancer | terminated | N/A | 180 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 23, 2023 | clinicaltrials |
| NCT04227275 | A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 16 | Tceleron Therapeutics, Inc.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 1 | Tceleron Therapeutics, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT00786682 | Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 11 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04575766 | A Study of FT-7051 in Men With MCRPC | terminated | Phase 1 | 25 | Novo Nordisk A/SINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| NCT00651326 | Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer(DART) | terminated | Phase 3 | 48 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05010759 | Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer | terminated | N/A | 3 | MagForce USAINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | terminated | Phase 1 | 74 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker | terminated | Phase 1 | 23 | AvenCell Europe GmbHINDUSTRY | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02640534 | Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | terminated | Phase 2 | 169 | Swiss Cancer InstituteOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT00002668 | Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer | terminated | N/A | 13 | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 22, 2023 | clinicaltrials |
| NCT01326312 | Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer(GTx758) | terminated | Phase 2 | 159 | GTxINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02516670 | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy(THRIP) | terminated | N/A | 2 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | terminated | Phase 3 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | terminated | Phase 1 / Phase 2 | 24 | Veru Inc.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT04077021 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 22 | Calibr, a division of Scripps ResearchOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT02968784 | Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer | terminated | N/A | 53 | InSightecINDUSTRY | 3 | May 9, 2023 | clinicaltrials |
| NCT03574194 | Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy | terminated | N/A | 8 | West Virginia UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03919214 | Hypertension Management in Cancer Patients | terminated | N/A | 4 | Duke UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer(CROSSBOW) | terminated | Phase 2 | 11 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT02844647 | Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer | terminated | Phase 1 | 2 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03440879 | Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose | terminated | N/A | 23 | Norwegian School of Sport SciencesOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04423913 | Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical Prostatectomy(CAPEMCHAR) | terminated | Phase 2 | 12 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT01709734 | A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer(ARMOR2) | terminated | Phase 2 | 126 | LTN PHARMACEUTICALS, INC.INDUSTRY | 2 | Mar 15, 2023 | clinicaltrials |
| NCT02438007 | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC(ARMOR3-SV) | terminated | Phase 3 | 953 | LTN PHARMACEUTICALS, INC.INDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT03439033 | Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer | terminated | Phase 2 | 273 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03921996 | Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer | terminated | Phase 3 | 57 | Swiss Cancer InstituteOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | terminated | Phase 3 | 38 | Timothy HoffmanFED | 1 | Feb 24, 2023 | clinicaltrials |
| NCT04873427 | In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies | terminated | — | 40 | Clinica Luganese MoncuccoOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02721979 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | terminated | Phase 2 | 24 | University of WashingtonOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02420652 | Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy(PRIMA) | terminated | Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT01045226 | Proton Radiation Therapy in Treating Patients With Prostate Cancer | terminated | N/A | 300 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer)(SHIP) | terminated | Phase 2 | 20 | Karyopharm Therapeutics IncINDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03796195 | (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes | terminated | Phase 4 | 1 | Northwestern UniversityOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT03111914 | Applications of Dual Energy CT in Patients With Osseous Metastases From Castrate-resistant Prostate Cancer | terminated | N/A | 7 | Duke UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04457245 | Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer(PSMA-dRT) | terminated | Phase 3 | 54 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT03365076 | Exercise for Improving Prostate Oxygenation in Prostate Tumors (Exipox)(EXIPOX) | terminated | N/A | 1 | University Hospital of North NorwayOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT02454517 | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer(PALS) | terminated | N/A | 117 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02745587 | Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.(PROPER) | terminated | Phase 3 | 69 | University Hospital, GhentOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT03971110 | A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. | terminated | Phase 4 | 9 | AstraZenecaINDUSTRY | 1 | Dec 16, 2022 | clinicaltrials |
| NCT04928820 | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy | terminated | Phase 2 | 22 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 21, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 13, 2023source: clinicaltrials